OpenAI, the maker of ChatGPT, is currently facing legal issues and regulatory scrutiny, and amid these troubles, it revealed its plan to appoint new board members.
OpenAI is expected to name several new board members this month as its regulatory problems pile up. According to The Washington Post, the company's board is moving closer to announcing new appointments after its recent organizational shakeup. At any rate, the information was shared by a source familiar with the matter and could not be named as the plan is still confidential.
Operating Without a Full Board
Since November 2023, OpenAI has been running the company without a full board. This happened as several members stepped down amid a leadership commotion that started when CEO Sam Altman was suddenly ousted.
Altman was reinstated after a wild backlash from investors and employees erupted. They also threatened to resign if the company did not bring back the fired chief. At that time, since the board was incomplete, they set up a new council that was meant to establish a new board.
Search for New Members
Reuters reported that when Altman returned, Bret Taylor, Salesforce's co-CEO, was assigned as chairman. Since then, OpenAI's new board has continued searching for six additional members. They hope to appoint executives who are experts in the technology, safety, and business policy fields.
Meanwhile, aside from Sam Altman, OpenAI's co-founder and president, Greg Brockman, are board members. They are joined by Quora's chief, Adam D'Angelo, and chief scientist, Ilya Sutskever. The previous board members who remained part of the group are technology entrepreneur Tasha McCauley and Helen Toner, the director of Georgetown Center for Security and Emerging Technology.
Photo by: Levart_Photographer/Unsplash


Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
Drugmakers Plan 2026 U.S. Price Increases on Over 350 Branded Medications Despite Political Pressure
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 



